Who we are

INTERPAT is a non-profit association of research-based biopharmaceutical companies that promotes effective intellectual property (IP) protection throughout the world as a key incentive of sustainable innovation to advance global health.  Its representatives are the leading and senior executives of its member companies who are responsible for IP and IP related matters.

Introduction to INTERPAT

INTERPAT was originally set up in the 1960s to provide advice on Intellectual Property matters from senior IP professionals to the management of its member companies. It later gained momentum as a biopharmaceutical industry organisation in its own right.

INTERPAT is unique amongst biopharmaceutical industry associations in that its Representatives are the senior IP or Patent counsel from its IP or Patents departments. These Representatives have extensive experience as both practising attorneys and senior managers. INTERPAT requests that the Principal Representative of a member company should be the Senior Patent or Senior IP counsel. If a company exercises its option to appoint a second (Associate) Representative, then that person should also be a senior department member.

Although delegation of attendance at INTERPAT meetings is permitted on request, INTERPAT strongly encourages that Representatives attend in person to ensure senior level presence with authority to speak and make decisions directly on behalf of its member companies.


The INTERPAT mission is to provide a forum for Intellectual Property leaders from the biopharmaceutical industry to achieve consensus and explore cross-industry support on priority Intellectual Property issues, and to deliver actions that shape the global environment of Intellectual Property to ensure sustainable innovation that advances health of the global population.



INTERPAT benefits from representation that comprises the leading and senior IP Counsels from the biopharmaceutical industry that are empowered to make strategic decisions on IP. This enables the sharing of knowledge, expertise, best/worst practices and experiences to build consensus on policy issues. INTERPAT also monitors and reviews IP legislation, IP Office practice, and IP enforcement.

  • It also serves as an incubator of new industry initiatives like World Intellectual Property Organization (WIPO) Re:Search and PatINFORMED, which have played a major role in positioning industry as a solution partner to global challenges.
  • INTERPAT will explore whether new or refined industry guidelines or principles would be useful in helping diffuse pressure on key areas of IP.


INTERPAT is well placed to gather the latest information and intelligence on the global IP landscape through its members country affiliates and extensive IP network.

  • It will continue to conduct a bi-annual IP-Threats Survey, which has become the bedrock for coordinated industry advocacy efforts on IP.
  • This network also allows INTERPAT to discuss real-time problems and issues that impact companies in key markets and agree on a suitable course of advocacy or policy action, often through the INTERPAT country or issue Workgroups. For example, where new laws and regulations are published for public consultation, INTERPAT reviews the published drafts and provides comments and suggestions, in line with defined priorities, and often cosponsors submissions with other leading industry associations.


INTERPAT works closely with other industry associations to ensure that policy development and advocacy deployment benefits from the full range of industry expertise and latest available information.

  • INTERPAT collaborates with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Japan Pharmaceutical Manufacturers Association (JPMA), taking guidance as required from relevant CEO roundtable discussions.

Collaboration, alignment and alliance creation with other innovative industries and trade associations, remains a key focus and allows for messaging to be transmitted through numerous channels and with different voices. They will be enhanced in 2018 through engagement with other non-industry actors, including academia and Non-Governmental Organizations (NGOs), with representatives with diverse experiences, attitudes and perspectives being invited to participate in INTERPAT General Assembly meetings.

INTERPAT will continue to enrich the public policy debate and/or expand technical competence on IP by organising international conferences and educational seminars, where industry input will underscore the importance of IP for sustainable innovation, patient access and economic growth.